Patient characteristics
| Age | Sex | BRAF | Tumor stage* | Treatment | Time to irAE/test† | Affected organ(s) | Grade (CTCAE 5)‡ | Treatment of irAE |
| 68 | M | V600K | IV | Ipi+Nivo | 2 months | Brain and spinal cord§ | 4 | CORT, MMF, IVIG, CP |
| 52 | F | Wt | IV | Ipi+Nivo | 2 months | Liver | 4 | CORT, MMF |
| 72 | F | Not known | IV | Pembro | 3 months | Blood (neutropenia) | 4 | CORT, filgrastim |
| 72 | M | V600 | IV | Pembro | 13 months | Colon | 3 | CORT, infliximab |
| 55 | F | V600 | IV | Nivo | 14 months | Joints and muscles | 3 | CORT, MTX |
| 38 | F | Wt | IV | Nivo¶ | 5 months | Joints and muscles | 3 | CORT |
| 83 | F | V600E | IV | Nivo | 1 month | Colon | 3 | CORT, infliximab |
| 53 | M | V600K | IV | Nivo | 11 months | Lungs | 2 | CORT |
| 80 | F | Wt | IV | Nivo | 10 months | Lungs | 2 | CORT |
| 74 | M | V600K | IV | Nivo±Relatlimab | 2 months | Joints and muscles | 2 | CORT |
| 71 | M | Wt | IV | Ipi+Nivo | 9 months | No irAE | 0 | none |
| 80 | M | Wt | IV | Ipi+Nivo | 2 months | No irAE | 0 | none |
| 80 | M | V600K | IV | Pembro | 5 months | No irAE | 0 | none |
| 77 | F | Wt | IV | Pembro | 4 months | No irAE | 0 | none |
| 82 | F | Wt | IV | Pembro | 3 months | No irAE | 0 | none |
| 76 | M | V600E | IV | Pembro | 3 months | No irAE | 0 | none |
| 67 | M | V600 | IV | Pembro | 2 months | No irAE | 0 | none |
| 68 | M | V600E | IV | Nivo | 4 months | No irAE | 0 | none |
| 62 | F | V600E | IV | Nivo | 3 months | No irAE | 0 | none |
| 57 | M | V600E | IV | Nivo | 2 months | No irAE | 0 | none |
| 68 | M | Wt | III | Nivo | 1 month | No irAE | 0 | none |
| 93 | M | Wt | III | Nivo | 1 month | No irAE | 0 | none |
*Stage III: locally advanced disease. Stage IV: metastatic disease.
†Time from treatment start until adverse event (and sample) or time from treatment start until sample in controls without irAE.
‡CTCAE are a set of criteria for the standardized classification of adverse effects of cancer drugs. The scale ranges from grade 0 to grade 5. Grade 0 is no adverse event. Grade one adverse events have no or mild symptoms with or without laboratory abnormalities whereas grade five events are lethal.
§Encephalomyelitis patient.
¶irAE during Nivolumab monotherapy. Ipi/Nivo treatment previously without any side effects.
CORT, corticosteroids; CP, cyclophosphamide; CTCAE, Common Terminology Criteria for Adverse Events; Ipi, ipilimumab; irAE, immune related adverse event; IVIG, intravenous immunoglobuline; MMF, mycophenolate mofetil; MTX, methotrexate; Nivo, nivolumab; Pembro, pembrolizumab; wt, wild type.